Youxin Chen
Youxin Chen is an expert in Ophthalmology at Peking Union Medical College Hospital (China). As of November 2026, ScienceLeadR ranks Youxin Chen in the top 1% of experts worldwide for Retinal Diseases, Diabetic Angiopathies and Diabetes Complications. Youxin Chen has authored 344 publications, the most recent in 2027, and is an investigator in 27 clinical trials, 4 of them ongoing. SLR score: 2,332 (community average: 125). How the SLR is computed.
LeadR Profile
Ophthalmology
Subspecialties: Immunology - Biochemistry - Surgery
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 1996 - 2027Chinese Academy of Medical Sciences & Peking Union Medical College
2012 - 2027
Peking Union Medical College Hospital
1996 - 2027
Number : 344
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
Clinical Studies 27
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Ongoing Clinical Trials
4 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| Efficacy and Safety of AL 001 Ophthalmic Injection in Subjects with WAMD NCT06839339 — injections, macular degeneration, vascular endothelial growth factor a, safety, intravitreal injections | Phase 2 | Not yet recruiting | 2025 |
| Efficacy and Safety of RC28 E Versus Aflibercept in Diabetic Macular Edema NCT05885503 — injections, safety, solutions, macular edema, ophthalmic solutions, intravitreal injections, edema | Phase 3 | Recruiting | 2023 |
| Clinical Implication of Aflibercept in PCV Treatment in China NCT05639660 — vascular diseases, therapeutics, prospective studies | N/A | Recruiting | 2021 |
| TAB014 Compared to Lucentis in Patients with Neovascular Age related Macular Degeneration NCT05461339 — injections, macular degeneration, safety, wet macular degeneration, antibodies, ranibizumab, antibodies, monoclonal, intravitreal injections | Phase 3 | Active not recruiting | 2022 |
LeadR Networks
Main global connection map